Tricyclic pyrone analogs: A new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo

Anti-Cancer Drugs

Volumn 10, Issue 5, 1999, Pages 489-504

  Perchellet, Elisabeth M ^a   Ladesich, James B ^a   Magill, Molly J ^a   Chen, Yi ^a   Hua, Duy H ^a   Perchellet, Jean Pierre ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; DNA cleavage; DNA synthesis; L1210 cell viability; Lewis lung carcinoma; Mitotic index; Nucleoside transport; Tubulin binding site and polymerization

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; DNA; GUANOSINE TRIPHOSPHATE; H 10; H 14; H 17; H 18; H 19; H 20; MAGNESIUM ION; PYRONE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE; H10; NUCLEOSIDE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DNA CLEAVAGE; DNA SYNTHESIS INHIBITION; DRUG STRUCTURE; LEUKEMIA CELL; LEWIS CARCINOMA; MICROTUBULE ASSEMBLY; MITOSIS INDEX; MOUSE; NONHUMAN; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; SOLID TUMOR; DRUG BINDING; FEMALE; LEUKEMIA L 1210; PROTEIN POLYMERIZATION;

EID: 0033408395     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199906000-00009     Document Type: Article

References (47)

1. Hua DH, Chen Y, Sin H-S, et al. A one-pot condensation of pyrones and enals. Synthesis of 1H, 7H-5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran. J Org Chem 1997; 62: 6888-96.
2. Robinson PD, Hua DH, Chen Y, Meyers CY. Structure of cis-3,5a-dimethyl-6-formyloxy-1H,7H-5a,6,8,9-tetrahydro-1- oxopyrano[4,3-b][1]benzopyran. Acta Cryst 1997; C53: 1642-4.
3. Hua DH, Chen Y, Robinson PD, Meyers CY. Structure of (5aS,7S)-7-isopropenyl-3-methyl-1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran. Acta Cryst 1997; C53: 1995-7.
4. Robinson PD, Beatty A, Hua DH, et al. Racemic 3-(3,4- dimethoxyphenyl)-1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyran, an antitumor agent formed from the condensation of 1-cyclohexenecarboxaldehyde with 4-hydroxy-6-(3,4-dimethoxyphenyl)-2-pyrone. Acta Cryst 1999; in press.
5. Perchellet JP, Newell SW, Ladesich JB, et al. Antitumor activity of novel tricyclic pyrone analogs in murine leukemia cells in vitro. Anticancer Res 1997; 17: 2427-34.
6. Newell SW, Perchellet EM, Ladesich JB, et al. Tricyclic pyrone analogs: a new class of microtubule-disrupting anticancer drugs effective against murine leukemia cells in vitro. Int J Oncol 1998; 12: 433-42.
7. Perchellet EM, Ladesich JB, Chen Y, et al. Antitumor activity of tricyclic pyrone analogs, a new synthetic class of microtubule de-stabilizing agents, in the murine EMT-6 mammary tumor cell line in vitro. Anti-Cancer Drugs 1998; 9: 565-76.
8. Chen H-X, Bamberger U, Heckel A, Guo X, Cheng Y-C. BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. Cancer Res 1993; 53: 1974-7.
9. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991; 3: 207-12.
10. Ishida R, Miki T, Narita T, et al. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991; 51: 4909-16.
11. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997; 57: 3208-13.
12. Engelborghs Y. Dynamic aspects of microtubule assembly. In: Avila J, ed. Microtubule proteins. Boca Raton, FL: CRC Press 1990: 1-35.
13. Borisy GG. A rapid method for quantitative determination of microtubule protein using DEAE-cellulose filters. Anal Biochem 1972; 50: 373-85.
14. Goldbrunner M, Loidl G, Polossek T, Mannschreck A, von Angerer E. Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-a]isoquinoline derivatives. J Med Chem 1997; 40: 3524-33.
15. Hamel E. Interaction of tubulin with small ligands. In: Avila J, ed. Microtubule proteins. Boca Raton, FL: CRC Press 1990: 89-191.
16. Arai T, Ihara Y, Arai K-I, Kaziro Y. Purification of tubulin from bovine brain and its interaction with guanine nucleotides. J Biochem (Tokyo) 1975; 77: 647-58.
17. Ling Y-H, Priebe W, Perez-Soler R. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug- resistant cells. Cancer Res 1993; 53: 1845-52.
18. Kolber MA, Broschat KO, Landa-Gonzalez B. Cytochalasin B induces cellular DNA fragmentation. FASEB J 1990; 4: 3021-7.
19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
20. Lai Y-L, Chen Y-J, Wu T-Y, et al. Induction of apoptosis in human leukemic U937 cells by tetandrine. Anti-Cancer Drugs 1998; 9: 77-81.
21. Brown JM. NCI's anticancer drug screening program may not be selecting for clinically active compounds. Oncol Res 1997; 9: 213-5.
22. 2+ dependence of guanine nucleotide binding to tubulin. J Biol Chem 1987; 262: 17278-84.
23. Johnson RK. Screening methods, in antineoplastic drug discovery. J Natl Cancer Inst 1990; 82: 1082-3.
24. Grindley GB. Current status of drug development: failure or limited success? Cancer Cells (Cold Spring Harbor) 1990; 2: 163-71.
25. De Brabander M, Geuens G, Nuydens R, et al. Tubulozole: a new stereoselective microtubule inhibitor. Ann NY Acad Sci 1986; 466: 757-66.
26. Koyanagi N, Nagasu T, Fujita F, et al. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 1994; 54: 1702-6.
27. Tsuruo T, Iida H, Naganuma K, Tsukagoshi S, Sakurai Y. Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug. Cancer Res 1983; 43: 808-13.
28. Bhattacharyya B, Wolff J. Promotion of fluorescence upon binding of colchicine to tubulin. Proc Natl Acad Sci USA 1974; 71: 2627-31.
29. Wallin M, Hartley-Asp B. Effects of potential aneuploidy inducing agents on microtubule assembly in vitro. Mutat Res 1993; 287: 17-22.
30. Luduena RF, Roach MC. Interaction of tubulin with drugs and alkylating agents. 2. Effects of colchicine, podophyllotoxin, and vinblastine on the alkylation of tubulin. Biochemistry 1981; 20: 4444-50.
31. Kobayashi T. Dephosphorylation of tubulin-bound guanosine triphosphate during microtubule assembly. J Biochem (Tokyo) 1975; 77: 1193-7.
32. Ben-Ze'ev A, Farmer SR, Penman S. Mechanisms of regulating tubulin synthesis in cultured mammalian cells. Cell 1979; 17: 319-25.
33. Wang T-H, Wang H-S, Ichijo H, et al. Microtubule-interfering agents activate c-jun N-terminal kinase/stress-activated protein kinase through both ras and apoptosis signal-regulating kinase pathways. J Biol Chem 1998; 273: 4928-36.
34. Lieu C-H, Chang Y-N, Lai Y-K. Dual cytotoxic mechanisms of submicromolar taxol on human leukemia HL-60 cells. Biochem Pharmacol 1997; 53: 1587-96.
35. Crawford CR, Ng CYC, Noel LD, Belt JA. Nucleoside transport in L1210 murine leukemia cells: evidence for three transporters. J Biol Chem 1990; 265: 9732-6.
36. Hammond JR. Comparative pharmacology of the nitrobenzylthioguanosine-sensitive and -resistant nucleoside transport mechanisms of Ehrlich ascites tumor cells. J Pharmacol Exp Ther 1991; 259: 799-807.
37. Dagnino L, Bennett LI. Jr, Paterson ARP. Sodium-dependent nucleoside transport in mouse leukemia L1210 cells. J Biol Chem 1991; 266: 6308-11.
38. Moorghen M, Ince P, Finney KJ, Watson AJ, Harris AL. Organ culture as a model for investigating the effects of antimetabolites and nucleoside transport inhibitors on rodent colonic mucosa. In Vitro Cell Dev Biol 1991; 27A: 873-7.
39. 5H]adenosine from rat brain synaptosomal preparations. J Neurochem 1995; 64: 2105-10.
40. Cory JG, Downes DL, Ng CYC, Belt JA. 5-Hexyl-2′-deoxyuridine inhibition of nucleoside transport in L1210 cells. Oncol Res 1992; 4: 175-9.
41. Vijayalakshmi D, Dagnino L, Belt JA, Gati WP, Cass CE, Paterson ARP. L1210/B23.1 cells express equilibrative, inhibitor-sensitive nucleoside transport activity and lack two parental nucleoside transport activities. J Biol Chem 1992; 267: 16951-6.
42. Morgan PF, Fine RL, Montgomery P, Marangos PJ, Multidrug resistance in MCF-7 human breast cancer cells is associated with increased expression of nucleoside transporters and altered uptake of adenosine. Cancer Chemother Pharmacol 1991; 29: 127-32.
43. Marina NM, Belt JA. Effect of nucleoside transport inhibitors on thymidine salvage and the toxicity of nucleoside analogs in mouse bone marrow granulocytemacrophage progenitor cells. Cancer Commun 1991; 3: 367-72.
44. Cao SS, Zhen YS. Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol 1989; 24: 181-6.
45. Hughes JM, Tattersall MHN. Potentiation of methotrexate lymphocytotoxicity in vitro by inhibitors of nucleoside transport. Brit J Cancer 1989; 59: 381-4.
46. Muggia FM, Slowiaczek P, Tattersall MHN. Characterization of conditions in which dipyridamole enhances methotrexate toxicity in L1210 cells. Anticancer Res 1987; 7: 161-6.
47. Parekh H, Wiesen K, Simpkins H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol 1997; 53: 461-70.